Provocative testing using low dose oral flecainide for diagnosis of Brugada syndrome: a report of two cases.

ABSTRACT:

Background

Brugada syndrome (BrS) is a genetic disease characterized by coved ST-segment elevation in the right precordial leads that predispose to life-threatening ventricular tachyarrhythmia. The electrocardiographic signature is dynamic and often concealed but can be unmasked by potent sodium channel blockers such as Flecainide. Some studies have evaluated the effectivity of oral Flecainide 400 mg for provocative testing, but clinical utility of lower dose Flecainide (300 mg) has never been documented.

Case summary

These two cases illustrate the effectiveness of low dose oral Flecainide to unmask Brugada electrocardiographic pattern. In our patients, diagnostic type 1 electrocardiography started to develop 30 min after drug administration and reached maximal positivity at

SUBMITTER: Amir M 

PROVIDER: S-EPMC9897198 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature